These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 24842595

  • 21. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Botting GM, Rastogi I, Chhabra G, Nlend M, Puri N.
    PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y, Wang Y, James M, Jeong JH, You M.
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S.
    Clin Cancer Res; 2010 Jan 01; 16(1):174-83. PubMed ID: 20008840
    [Abstract] [Full Text] [Related]

  • 26. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
    Yamaoka T, Ohmori T, Ohba M, Arata S, Murata Y, Kusumoto S, Ando K, Ishida H, Ohnishi T, Sasaki Y.
    Mol Cancer Res; 2017 Jul 01; 15(7):915-928. PubMed ID: 28289161
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.
    Clin Cancer Res; 2011 Apr 15; 17(8):2260-9. PubMed ID: 21220474
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
    Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, Poklepovic A, Dent P.
    Oncotarget; 2016 Apr 12; 7(15):19620-30. PubMed ID: 26934000
    [Abstract] [Full Text] [Related]

  • 36. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
    Yun M, Kim EO, Lee D, Kim JH, Kim J, Lee H, Lee J, Kim SH.
    Cell Physiol Biochem; 2014 Apr 12; 34(3):865-72. PubMed ID: 25199820
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
    Li K, Zhou F, Zhou Y, Zhang S, Li Q, Li Z, Liu L, Wu G, Meng R.
    Int J Mol Med; 2019 Aug 12; 44(2):437-446. PubMed ID: 31173177
    [Abstract] [Full Text] [Related]

  • 39. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.
    Mol Cancer Ther; 2015 Feb 12; 14(2):533-41. PubMed ID: 25522765
    [Abstract] [Full Text] [Related]

  • 40. [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
    Zhou Y, Zhang S, Li K, Li QW, Zhou FZ, Li ZY, Ma H, Dong XR, Liu L, Wu G, Meng R.
    Zhonghua Zhong Liu Za Zhi; 2016 Feb 12; 38(2):100-4. PubMed ID: 26899328
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.